Saving Lives by Restoring Muscles
Sarcomatrix Therapeutics, a biotechnology company focused on developing innovative treatments for muscle diseases, is pleased to announce the addition of Al Swarts as Chief of Technical Operations.
This strategic hire underscores the company’s commitment to building a strong infrastructure to support its IND filing and first-in-human clinical trials, scheduled for 2025.
Al Swarts brings extensive experience in supply chain & technical operations along with strong program management expertise guiding companies through the drug development and commercialization journey. His expertise will play a pivotal role in advancing Sarcomatrix’s lead programs, ensuring the company meets critical milestones in its journey to bring life-changing therapies to patients.
“Al’s proven track record in operational excellence and his deep understanding of chemistry, manufacturing, and controls (CMC) and clinical development processes make him an invaluable addition to the Sarcomatrix team,” said David Craig, CEO of Sarcomatrix Therapeutics. “As we move closer to our IND submission and clinical trials, his leadership will be instrumental in driving our success.”
Sarcomatrix is dedicated to addressing the urgent needs of patients with muscle diseases, where timely intervention can make a significant impact on quality of life. The addition of Al Swarts reflects the company’s focus on assembling a world-class team to deliver on its mission.
For more information about Sarcomatrix Therapeutics and its innovative drug development pipeline, visit www.sarcomatrix.com.
Media Contact:
Investor Relations
ir@sarcomatrix.com
01-775-525-1795
About Sarcomatrix Therapeutics:
Sarcomatrix Therapeutics is a biotechnology company developing novel therapies for muscle diseases. With a robust pipeline and a focus on scientific excellence, Sarcomatrix is committed to transforming the lives of patients through innovative treatments.
David Craig
Sarcomatrix, Inc.
+1 415-246-3311
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
